You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

182 Results
Guidelines and Advice
Status: Current
ID: GL-C50-13
Feb 2014
Guidelines and Advice
Status: Current
ID: GL-C50-11
Jan 2014
Guidelines and Advice
Status: Current
ID: GL-C50-14
Mar 2014
Statistical Reports
Jan 2014
Statistical Reports
Apr 2014
Guidelines and Advice
Status: Current
Jun 2014
Guidelines and Advice
Jul 2014
Guidelines and Advice
Status: Current
ID: GL-C50-15
Jun 2014
Drug
Other Name(s): Trelstar® (Allergan Pharma)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2014
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
gemcitabine,
oxaliplatin,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2026
Drug
Other Name(s): Darzalex®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2026

Pages